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Aging represents one of the most complicated and highly integrated somatic processes. 
Healthy aging is suggested to rely upon the coherent regulation of hormonal and 
neuronal communication between the central nervous system and peripheral tissues. 
The hypothalamus is one of the main structures in the body responsible for sustaining 
an efficient interaction between energy balance and neurological activity and therefore 
likely coordinates multiple systems in the aging process. We previously identified, in 
hypothalamic and peripheral tissues, the G protein-coupled receptor kinase interacting 
protein 2 (GIT2) as a stress response and aging regulator. As metabolic status profoundly 
affects aging trajectories, we investigated the role of GIT2 in regulating metabolic activity. 
We found that genomic deletion of GIT2 alters hypothalamic transcriptomic signatures 
related to diabetes and metabolic pathways. Deletion of GIT2 reduced whole animal 
respiratory exchange ratios away from those related to primary glucose usage for energy 
homeostasis. GIT2 knockout (GIT2KO) mice demonstrated lower insulin secretion levels, 
disruption of pancreatic islet beta cell mass, elevated plasma glucose, and insulin resis-
tance. High-dimensionality transcriptomic signatures from islets isolated from GIT2KO 
mice indicated a disruption of beta cell development. Additionally, GIT2 expression was 
prematurely elevated in pancreatic and hypothalamic tissues from diabetic-state mice 
(db/db), compared to age-matched wild type (WT) controls, further supporting the role 
of GIT2 in metabolic regulation and aging. We also found that the physical interaction of 
pancreatic GIT2 with the insulin receptor and insulin receptor substrate 2 was diminished 
in db/db mice compared to WT mice. Therefore, GIT2 appears to exert a multidimen-
sional “keystone” role in regulating the aging process by coordinating somatic responses 
to energy deficits.
Keywords: giT2, metabolism, keystone, aging, dysglycemia, trajectory
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inTrODUcTiOn
The natural aging process is associated with an accumulation 
of molecular perturbations affecting almost all cells, tissues and 
organs of the body. These alterations have long been known 
to affect multiple processes related to cell survival, genomic 
instability, altered gene expression patterns, aberrant cellular 
replication, oxidative damage by reactive oxygen species (ROS), 
and fluctuations in protein expression and coherent protein 
post-translational modification (1). Life expectancy in most 
westernized and developing countries is demonstrating an 
inexorable increase (2, 3), therefore either natural or pathological 
aging could be considered the primary threat to global health in 
the future. With increasing age, there is a system-wide reduction 
in the ability of the body to cope with stress in-part due to a 
degradation of the efficiency of energy-generating [e.g., ATP 
(adenosine triphosphate)] metabolic systems (4–6). Disruption 
of the primary energy-synthesizing system, i.e., glucose catabo-
lism by oxidative phosphorylation, leads to both ATP depletion 
(thus affecting electrical cellular excitability, proteolytic activi-
ties, transmembrane transport processes, and kinase activity) 
as well as an increase in the deleterious effects of unregulated 
hyperglycemia, e.g., systemic inflammation, arterial stenosis, 
impaired tissue healing, neuronal damage, and renal failure. 
Hence, one of the most characteristic factors in the aging process 
are the generation of insulin resistance, disruptions to oxidative 
phosphorylation of glucose, and changes in body fat composi-
tion (6). Therapeutic interventions, such as caloric restriction or 
visceral fat depletion, designed to address features of metabolic/
glycemic aging, have succeeded in improving insulinotropic 
activity and life span in rodents (7, 8). The importance of the effi-
ciency in glucose metabolism in the aging process is underscored 
by the demonstration that multiple glucose-regulatory factors 
in nematode worms were also major age-regulating genes, e.g., 
daf-2 [insulin receptor analog (9)] and age-1 [phosphoinositide 
3-kinase analog – a primary downstream factor of insulin recep-
tor functions (10)]. Translation of these fundamental insulin/
glucose-mediated life span alterations from nematodes to higher 
organisms has proven problematical: a situation likely due to the 
increased functional diversity of insulin/insulin-related ligands 
in more complex, higher organisms. Despite this however, 
adipose tissue-specific insulin receptor deletion is associated 
with life span alterations in mice (11). Linked to this observa-
tion, experimental paradigms in rhesus macaques that attenuate 
age-related glycemic disruption and increase insulin sensitivity 
(i.e., caloric restriction) can significantly reduce the incidence of 
age-dependent pathologies (12).
Due to the gradual loss of metabolic integrity with increasing 
age, the body becomes more prone to a variety of pathophysiolo-
gies linked to energy insufficiency such as neurodegeneration, 
metabolic syndrome (MetS), and chronic inflammation. These 
accumulated and progressive changes in complex physiological 
systems such as the endocrine or central nervous system (CNS) 
are highly likely to be mediated by gene and protein groups that are 
trophically controlled by “keystone” or “hub” factors that orches-
trate the communication between lower-complexity functional 
signaling networks (13). Considerable research demonstrates 
that both neurodegenerative diseases and pathophysiological 
aging involve a functional interplay between a series of diverse 
biological systems including neurological, endocrinological, 
sensory, and metabolic activities (13–23). Many of these systems 
are functionally integrated together in one crucial CNS organ, 
i.e., the hypothalamus (24). The hypothalamus is responsible for 
the regulation of many metabolic pathways by synthesizing and 
secreting numerous neuronal hormones that stimulate or inhibit 
the secretion of trophic hormones from the anterior pituitary. 
The hypothalamus therefore can control global metabolism, body 
temperature, thirst, hunger, fatigue, and circadian rhythms (25). 
Not only does the hypothalamus act as a trophic master-controller 
of the endocrine system but it also possesses neuronal projections 
to many autonomous and higher centers of the brain (26), thereby 
providing a crucial link between aging and age-related disorders 
such as dementia (27). We have previously shown, through the 
development of in cellula aging models (19), that regulation of the 
G protein-coupled receptor kinase interacting protein 2 (GIT2) 
is highly sensitive to the chronological aging process and also to 
the presence of age-linked stressors such as ROS. Using a combi-
natorial informatics and proteomics approach, we demonstrated 
that GIT2 acts as a hypothalamic aging “keystone” factor (13). 
Subsequently, GIT2 has also been implicated in regulating DNA 
integrity via its interaction with ataxia telangiectasia-mutated 
(ATM), a DNA damage repair (DDR) kinase (18). In response to 
multiple forms of DNA damaging insults, GIT2 is rapidly phos-
phorylated by ATM and then forms a complex with multiple DDR 
proteins including MDC1, MRE11, and phosphorylated H2AX 
(18). Genomic deletion of GIT2 in mice (GIT2KO) resulted in 
a significant increase in the rate of DNA damage accumulation 
compared to wild type (WT) age-matched control mice (18). DNA 
instability has been associated with an advanced rate of aging for 
several decades (28–30) and this has been reinforced with the 
appreciation that accelerated molecular aging occurs in patients 
possessing mutations in multiple DDR proteins including ATM 
(31), WRN [Werner syndrome, RecQ helicase-like (32, 33)], 
and BLM [Bloom syndrome, RecQ helicase-like (34)]. Glucose-
related diabetic pathologies often result in elevated cellular levels 
of ROS due to an attenuated glucose uptake capacity and support 
of oxidative phosphorylation causing cells to generate ATP via 
other less-efficient synthetic mechanisms. Prematurely elevated 
ROS levels, as with mutations in DDR proteins, are considered to 
be one of the major causes of advanced aging (35–37). Reinforcing 
the link between dysfunctional aging, diabetic pathologies, and 
DNA instability, DDR proteins such as ATM are repeatedly linked 
to impaired insulin secretion capacity and diabetic pathophysi-
ologies (38–41). Therefore, given the demonstration of a crucial 
hypothalamic function of GIT2 both in the aging process and 
DNA integrity management, we investigated the potential role 
of this G protein-coupled receptor (GPCR)-interacting protein 
in controlling/coordinating glycemic or metabolic functions in 
the context of aging. We have analyzed the molecular metabolic 
signatures of pathological aging in mice at a relatively early phase 
of life, i.e., 2–8  months of life (approximately 10–30% of life 
span), in a similar vein to the human aging trajectory study of 
Belsky et al. (42). In the study of Belsky et al., it was suggested that 
research into the molecular mechanisms of aging are significantly 
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confounded, both with animal models and human patients, by 
the accumulation of extraneous co-pathologies during life span 
(42). However, it is also likely that dysfunctional molecular aging 
paradigms are set in place during early life that effectively define 
either a pathological or “less-pathological (healthy)” aging tra-
jectory (43–45). Here, we have found that high-dimensionality 
molecular transcriptomic signatures of pathological aging and 
pro-diabetic pathologies occur early in life and that GIT2 con-
trols global somatic metabolism, circulating levels of multiple 
plasma energy-regulating hormones and pancreatic beta cell 
functionality.
MaTerials anD MeThODs
cell culture
Murine Beta-TC-6 cells (ATCC1) were maintained in a humidi-
fied 5% CO2 environment at 37°C in Dulbecco’s modified Eagle’s 
medium (DMEM) media (Life Technologies, Carlsbad, CA, USA) 
supplemented with 15% heat-inactivated fetal bovine serum and 
1% penicillin–streptomycin (Life Technologies, Carslbad, CA, 
USA). Murine GIT2 siRNA (Santa Cruz) was generated as a 
pool of three target-specific 19–25 nt siRNAs. Control siRNA-A 
consists of a scrambled sequence that does not induce specific 
degradation of any cellular mRNA. Cells were transfected with 
siRNA oligonucleotides using Lipofectamine RNAi MAX (Life 
Technologies, Carlsbad, CA, USA) according to the manufac-
turer’s protocol. To assess cell viability after any specific long-term 
treatment, cells were first washed in phosphate buffered saline 
(PBS: Sigma-Aldrich, St. Louis, MO, USA) and then collected 
from the growth plates using calcium-free, non-enzymatic cell 
dissociation solution (Sigma-Aldrich, St. Louis, MO, USA). 
Cells were gently pelleted by centrifugation at 1000 × g at room 
temperature before being resuspended in a Hanks’ Balanced Salt 
solution (cat.#H9269: Sigma Aldrich) and mixed with a 0.4% 
Trypan Blue solution and allowed to incubate for 15 min at room 
temperature. Cells were then transferred to a Bright-Line™ 
hemacytometer (Sigma-Aldrich) and a percentage of positive 
blue cells (representing cells possessing a severely compromised 
plasma membrane and thus at high risk of imminent death) were 
counted by an experienced researcher. As a positive control for 
loss of cell viability, cell cultures were pre-incubated with a 2 μg/
ml concentration of actinomycin D (Sigma-Aldrich) for 2  h 
before collection and Trypan Blue processing as described here 
previously.
experimental animal Models
G protein-coupled receptor kinase interacting protein 2 gene-trap 
knockout (KO) mice (GIT2KO), were originally obtained from Dr. 
Richard T. Premont (Duke University Medical Center, Durham, 
NC, USA) and genotyped using genomic PCRs as previously 
described (46). PCR amplification was performed by standard 
protocols. Primers used to screen the GIT2 knockout mice were 
as follows: forward primer 5′-TCTCCTGGAACTCAGGGATT, 
reverse primers (WT) 5′-CATTTCAGAGTCTGCTGCCTTA 
1 www.atcc.org/
and (KO) 5′-GGCTACCGGCTAAAACTTGA. Male WT (WT: 
C57BL/6) and GIT2KO mice were group-housed (genotypes 
were housed separately) in temperature-controlled (22°C) and 
humidity-controlled (45%) rooms with a 12 h light–dark cycle 
with food and water available ad libitum. Male leptin receptor-
mutant (db/db) mice, bred on a C57BL/6 background, were 
purchased from The Jackson Laboratories.2 All experimental 
mouse models were fed using a standard control animal chow 
containing 19% protein, 64% carbohydrates, and 17% fat (diet 
#101845 from Dyets Inc., Bethlehem, PA, USA). Experiments 
were conducted during the light phase of the light–dark cycle in 
accordance with NIH guidelines. Animal care and experimental 
procedures followed NIH guidelines and were approved by the 
National Institute on Aging Animal Care and Use Committee 
(433-LCI-2015).
Whole animal glycemic Function Testing
Standard insulin tolerance tests (ITT), applied according 
to Jackson Laboratory handling protocols,3 involved blood 
glucose sampling from a distal tail snip after the specified 
time (0–90  min) of a subcutaneous Lantus® (0.5  U/kg) bolus. 
Standard oral glucose tolerance tests (OGTT) were made using 
standardized protocols (47–49). Briefly, mice were fasted for 
4  h, and blood was drawn from the tail and gathered using a 
heparinized micro-hematocrit capillary tube (Fisher Scientific, 
Pittsburgh, PA, USA), and clotisol (Agri-Med, St. Louis, MO, 
USA) was used to stop the bleeding. Mice were then adminis-
tered with glucose (2 g/kg) via gavage and blood samples drawn 
at the specified time in minutes after glucose administration. For 
all time points, whole-blood glucose concentration was quanti-
fied at the time of blood draw using a Freestyle Glucose meter 
(Abbott Laboratories, Abbott Park, IL, USA). Blood samples 
were then centrifuged at 12,500  rpm for 12  min at 4°C, and 
plasma supernatant was removed and stored at −80°C. Insulin 
was quantified using a commercially available ELISA kit (Crystal 
Chem Inc., Downers Grove, IL, USA).
Whole-Body Murine Metabolic and 
Behavioral analyses
Murine behavior and metabolic parameters were measured, over 
a 48-h period, using a Columbus Instruments Comprehensive 
Lab Animal Monitoring System (CLAMS). The CLAMS 
system was used to evaluate food intake (gram), water intake 
(milliliter), X, Z total activity (counts), O2 consumption (mil-
liliter/kilogram/hour), CO2 production (milliliter/kilogram/
hour), and respiratory exchange ratio (RER = VCO2/VO2), as 
described previously with modifications (50–52). Eight mice 
per group were single housed for 24 h in the system. The mean 
weight of WT-control mice (27.25 ±  0.69  g) was slightly less 
but not significantly different from the GIT2KO counterparts 
(29.06 ± 1.17 g). Statistical analysis was performed using a two-
tailed Student’s t-test, and p ≤ 0.05 was considered statistically 
significant.
2 http://jaxmice.jax.org/index.html
3 http://jaxservices.jax.org/glucosetolerance_protocol.html
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Measurement of glucose, lipids, and 
hormone levels
Blood was collected after the mice were euthanized with isoflurane. 
Eight to ten animals were included in each group. Glucose levels 
were measured using an EasyGluco blood glucose monitoring 
system (US Diagnostics, Inc.). For fasting glucose measurements, 
mice were food-deprived 12 h prior to blood collection. Plasma 
insulin, leptin, peptide YY (PYY), gastric inhibitory peptide 
(GIP), amylin, and pancreatic peptide (PP) levels were measured 
using Linco-Millipore multiplex kit (53, 54). Briefly, plasma 
samples were incubated together with antibody conjugated beads 
for 16 h at 4°C. After three times washing, biotinylated detection 
antibody was added: these were further incubated for 1 h at room 
temperature, and then streptavidin–horseradish peroxidase 
was added. Fluorescent signals were detected by Bio-Plex 200 
systems. Each sample was assayed in duplicate on a 96-well plate. 
Hormone levels were derived by interpolation from a reference 
curve generated in the same assay with reference standards of 
known concentrations of the detected hormones.
Pancreatic Tissue and islet extraction
As described previously (53), mice were euthanized with isoflu-
rane followed by decapitation. Whole pancreata were removed 
from each animal. The pancreata were then processed differen-
tially concerning their eventual usage. For immunohistochemi-
cal analyses, the pancreata were fixed in 4% formalin for 48  h 
and stored in PBS until processing. The pancreatic tissue was 
processed and embedded in paraffin wax. Pancreatic sections 
were cut at 5 μm thickness using a microtome, and the sections 
were adhered to poly-l-lysine-coated microscope slides (Fisher, 
Springfield, NJ, USA). For analysis of insulin- (beta cells) and 
glucagon- (alpha cells) secreting islet cells, pancreatic sections 
were immunostained according to a previously described proto-
col (53). Briefly, the tissue was incubated with the primary insulin 
antibody (guinea pig anti-swine insulin; 1:300; DakoCytomation, 
Carpinteria, CA, USA) or glucagon antibody (1:500; guinea pig 
anti-glucagon; Millipore, Billerica, MA, USA) for 2  h at room 
temperature and then incubated with secondary antibody [Alexa 
Fluor 488 (AF488) goat anti-–guinea pig, 1:200; or Alexa Fluor 
568 (AF568) goat anti–guinea pig, 1:1,000; Life Technologies, 
Carlsbad, CA, USA] for 1 h at room temperature. Sections were 
imaged with an Olympus Fluoview IX70 microscope (Olympus 
America, Center Valley, PA, USA). Quantification of immuno-
histochemistry images was performed in MATLAB (Mathworks) 
using novel software in conjunction with the image processing 
toolbox. Intensity readings of each image ranged from 0 to 256, 
with 256 being the greatest pixel density and hence the highest 
staining intensity. The region of interest (ROI) was drawn around 
each islet after background subtraction. The pixels within the 
bounds of the ROI and above the set threshold of eight were 
selected, from which the actual islet area was calculated. The 
normalized variance of the ROI was used to calculate an artificial 
ellipse from which the major and minor axes were determined. 
The major axis is the longest diameter that can be drawn in the 
ellipse, and the minor axis is the shortest diameter, both giv-
ing an accurate approximation for the range of the actual islet 
diameter. Islet morphometry and sizing analyses were performed 
in an unbiased, random fashion (55). Specific murine islets were 
isolated using collagenase digestion, using the same protocol as 
described previously (56). Murine islets suspended in DMEM-
containing 5 mM glucose and 1% bovine serum albumin (BSA) 
were pelleted and stored before extraction of total RNA for 
microarray analysis.
Bioinformatic analyses
Microarray-derived gene transcript lists were initially separated 
into specific expression polarity regulation groups using VennPlex 
venn diagram analysis (57) before pathway analysis using multiple 
forms [KEGG pathway using WebGestalt (58), Ingenuity Pathway 
Analysis (IPA) Canonical Signaling, Textrous!-based natural 
language processing (59)] of functional annotational clustering. 
For KEGG and IPA Canonical Pathway signaling analysis, we 
employed a cutoff of at least two transcripts (from the original 
filtered/analysis of variance datasets) needing to be present to 
minimally populate a particular canonical IPA or KEGG pathway 
with a probability (p) of enrichment value of ≤0.05. Where stated, 
a hybrid score process was employed to generate a single index 
for a specifically enriched KEGG pathway. Hybrid scores were 
generated by the multiplication of the negative log10 of enrich-
ment probability (p) with the enrichment factor (R). Latent 
Semantic Indexing (LSI)-based analysis (60) was performed 
as described previously using Textrous! (59). Textrous! as well 
as other LSI-based informatics platforms (e.g., GeneIndexer), 
correlate the strength of association, using LSI (13, 19), between 
specific transcripts in a dataset with user-defined interrogation 
terms. Textrous! is able to investigate connections between input 
transcripts/proteins (using input Gene Symbols) and biomedical 
words and noun-word phrases using complete extracted data 
(in the form of curated gene-word documents) from PubMed 
Central,4 OMIM (Online Mendelian Inheritance in Man5), and 
the Mammalian Phenotypes Database at the Jackson Laboratories 
Mouse Genomic Informatics portal.6 For Textrous!-based natural 
language processing, the possible LSI correlation scores (termed 
Cosine Similarity Scores) for a gene/protein to be associated with 
an input interrogation term range from 0 to 1, with the stronger 
correlation scores approaching 1. A correlation score of ≥0.1 
indicates at least an implicit correlation, between the specific gene 
and the user-defined input interrogation term (61). To generate 
a holistic and more specific high-dimensionality data annotation 
for Textrous!-based text outputs, significant data word clouds 
were created from the Textrous!-based semantic noun and noun-
phrase outputs using the web-based application Wordle7 (62). The 
text size within the word clouds is directly proportional to the 
input word frequency. Analyses of word-phrase frequencies from 
Textrous! noun-phrase outputs were made using WriteWords.8 
The use of freeform quantitative wordclouds to convey complex 
non-canonical signaling-activity relationships is becoming more 
4 http://www.ncbi.nlm.nih.gov/pmc/
5 http://www.ncbi.nlm.nih.gov/omim
6 http://www.informatics.jax.org/
7 http://www.wordle.net/
8 http://www.writewords.org.uk/word_count.asp
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and more recognized as a novel technique to investigate high-
dimensionality data (63–65).
immunoprecipitation assays
Whole murine pancreata, WT or db/db, were extracted through 
micro-dissection. For protein immunoprecipitation, cytoplasmic 
cell lysates were prepared using the Qproteome® cell compart-
ment kit according to the manufacturer’s instructions (Qiagen, 
Valencia, CA, USA) and as described here. All protein extracts 
were quantified using BCA reagent (ThermoScientific, Waltham, 
MA, USA) before normalization to a standard 1 mg/ml protein 
concentration before immunoprecipitation. Normalized superna-
tant protein lysates were pre-cleared by a 1 h incubation, tumbling 
at 4°C, with 30 μl of protein A/G pre-conjugated agarose beads 
(EMD Chemicals, Gibbstown, NJ, USA). For immunoprecipita-
tion, the pre-cleared cell lysates were then incubated overnight for 
16 h at 4°C with tumbling with 10 μg of either pre-immune IgG 
sera (Sigma-Aldrich, St. Louis, MO, USA) or 10 μg of anti-GIT2 
antibody (Bethyl Laboratories, Montgomery, TX, USA). To col-
lect the immunecomplexes, 30 μl of protein A/G pre-conjugated 
agarose beads (EMD Chemicals, Gibbstown, NJ, USA) were added 
to the lysates and then tumbled at 4°C for an additional hour. 
The agarose-associated immunecomplexes were then collected by 
centrifugation at 2000 × g for 5 min. Immunoprecipitated protein 
complexes were removed from the agarose-associated antibodies 
by the addition of 50 μl of a room-temperature CHAPS-Urea buffer 
[4% CHAPS ((3-((3-cholamidopropyl) dimethylammonio)-
1-propanesulfonate) (Sigma-Aldrich, St. Louis, MO, USA), 8M 
Urea)] through gentle agitation before being stored at −80°C for 
further mass spectrometry (MS)-based processing.
Mass spectrometry
Proteins were extracted from GIT2 immunoprecipitates using 
4% CHAPS-8M Urea and were analyzed using reverse-phase 
nano LC-MS/MS on a ThermoFinnigan LXQ linear ion MS 
(ThermoFinnigan, West Palm Beach, FL, USA) as described 
previously (66). Analytical samples were separated on an in-house 
fabricated 8-cm reverse-phase capillary emitter column or a c18 
PicoFrit column (New Objectives, Boston, MA, USA), using 
90 min gradients. The collision energy for the LXQ MS was set at 
30%. Spectra were acquired in a data-dependent manner with the 
dynamic exclusion option enabled. The four most intense ions in 
each full MS scan were fragmented and analyzed. MS/MS spectral 
data were processed using MASCOT Daemon v. 2.2.2 (Matrix 
Science) for protein identification. For the MS/MS ion search 
using MASCOT, proteins with >1 peptides and a score of each 
peptide higher than 45 with an unambiguous identification were 
considered for further analysis without manual spectra inspec-
tion. Proteins with one peptide and a score lower than 45 were 
considered ambiguous and discarded from analysis. We used the 
pre-defined enzyme specificity in the Mascot Daemon v. 2.2.2. 
Search parameters included static mass modification to cysteine 
(iodoacetamide alkylation) and differential mass modification to 
methionine (oxidation). The decoy database option provided by 
MASCOT was selected to determine false discovery rates (FDR), 
which was kept below 1% by applying various significance thresh-
olds to each search result.
Western Blotting
Murine hypothalami or pancreata were extracted through micro-
dissection, and cell lysates were also prepared from murine TC6 
cells. For protein extraction, differential cellular compartment 
(cytoplasm, plasma membrane, nuclear/large organelle, and 
cytoskeleton) lysates were prepared using the Qproteome® cell 
compartment kit according to the manufacturer’s instructions 
(Qiagen, Valencia, CA, USA). All protein extracts were quantified 
using BCA reagent (ThermoScientific, Rockford, IL, USA) and 
then normalized for each specific experiment before resolution 
with SDS-PAGE and semi-dry electrotransfer (Bio-Rad, Hercules, 
CA, USA) to PVDF membranes (PerkinElmer Life Sciences; 
Waltham, MA, USA). Membranes were blocked using a 4% BSA 
for Western blot as described previously (67), and primary anti-
body immune-reactive complexes were identified using alkaline 
phosphatase-conjugated secondary antisera (Sigma-Aldrich, St. 
Louis, MO, USA) with enzyme-linked chemifluorescence (GE 
Healthcare) and visualized with a Typhoon 9410 phosphorimager 
(GE Healthcare). Proteins were identified using primary antisera at 
1:1,000 to 1:10,000 dilutions, followed by species-specific alkaline 
phosphatase-conjugated secondary antibodies (Sigma-Aldrich, 
St. Louis, MO, USA) at 1:7,000 dilution. The primary antibodies 
employed in this study are described in the next section.
experimental antibodies
Primary antibodies specific for diablo homolog (Drosophila) 
(Diablo: ab8114), glyoxalase 1 (Glo1: 6F10: ab81461), sestrin 1 
(Sesn1: ab103121), insulin receptor (Insr: ab5500), insulin recep-
tor substrate 2 (Irs2: ab134101), p53 and DNA damage regulated 
1 (Pdrg1: ab74500), plasma membrane Ca2+ ATPase (Pmca: 
ab2825), and tubulin alpha-1A (Tuba1a: ab76449) were obtained 
from Abcam (Cambridge, MA, USA). Primary antibodies specific 
for phosphatidylethanolamine binding protein 1 (Pebp1: clone 
EPR2875Y: C105420) and high mobility group nucleosomal 
binding domain 2 (Hmgn2: C151267) were obtained from LSBio 
(Seattle, WA, USA). Primary antibodies specific for receptor 
accessory protein 5 (Reep5: H-76), extracellular signal-regulated 
kinase 2 (Erk2: C-8), glucose transporter 2/solute carrier family 2 
(facilitated glucose transporter), member 2 (Glut2/Slc2a2: H-67), 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh: I-19), mito-
chondrial ribosomal protein L12 (Mrpl12: 397.1), F-box protein 
24 (Fbxo24: D-14) microtubule-associated protein 1 A (Map1a: 
N-18), CASK-interacting protein 2 (Caskin2: P-13), and lamin 
A (Lmna: C-20) were obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). Primary antibodies specific for double-
cortin (Dcx: #4604), ataxia telangiectasia mutated (Atm: #2873), 
beta-PIX (Arhgef7: #4515), and p21-activated kinase 1 (Pak1: 
#2602) were obtained from Cell Signaling Technology (Danvers, 
MA, USA). The primary antibody specific for regenerating islet-
derived 3 beta (Reg3b: Clone 518630) was obtained from R&D 
Systems (Minneapolis, MN, USA). Primary antibodies specific 
for NADH dehydrogenase (ubiquinone) 1 beta subcomplex and 
10 (Ndufb10: 15589-1-AP) and ribosomal protein L17 (Rpl17: 
14121-1-AP) were obtained from ProteinTech (Chicago, IL, 
USA). The primary antibody specific for Finkel–Biskis–Reilly 
murine sarcoma virus (FBR-MuSV) ubiquitously expressed 
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(fox derived) (Fau: NBP1-55090) was obtained from Novus 
Biologicals (Littleton, CO, USA). Primary antibodies specific 
for G protein-coupled receptor kinase-interactor 2 (Git2: A302-
102A) and structural maintenance of chromosomes protein 5 
(Smc5: A300-236A) were obtained from Bethyl Laboratories Inc. 
(Montgomery, TX, USA).
Differential Detergent cellular 
Fractionation
For cellular differential detergent fractionation, cell lysates were 
prepared using the Qproteome® cell compartment extraction 
kit (cat# 37502) according to the manufacturer’s instructions 
(Qiagen, Valencia, CA, USA) with minor modifications. In brief, 
cultured cells were first washed in ice-cold phosphate buffered 
saline (PBS: Sigma-Aldrich, St. Louis, MO, USA) and then col-
lected from the plate using ice-cold calcium-free cell dissociation 
solution (Sigma-Aldrich, St. Louis, MO, USA). Intact cell pellets 
were created by centrifugation at 1000 ×  g at 4°C. Cell pellets 
were then solubilized in the pre-cooled Qproteome proprietary 
cytoplasmic protein extraction buffer (CE1: 500 μl), which was 
supplemented with 1× of the kit Protease Inhibitor Solution. The 
lysates were then tumbled in the cytoplasmic CE1 buffer for 10 min 
at 4°C. The CE1 lysate was then centrifuged at 1000 × g for 10 min 
at 4°C. The supernatant was then removed to a fresh Eppendorf 
tube to generate the cytoplasmic tissue extract. The extant cell 
pellet was then solubilized in 500 μl of ice-cold CE2 plasma mem-
brane extraction buffer supplemented with 1× of the kit Protease 
Inhibitor Solution and then tumbled at 4°C for 30 min. The lysate 
was then clarified by centrifugation at 6000 × g for 10 min at 4°C. 
The supernatant, representing the plasma membrane enriched 
compartment was removed to a fresh Eppendorf tube, and the 
extant pellet was then incubated with 7 μl of Qproteome-supplied 
Benzonase® Nuclease and 13 μl of distilled water, mixed through 
gentle agitation and then incubated at standard room tempera-
ture (21–24°C) for 15 min. The pellet was then solubilized, with 
additional pipette trituration, in 250 μl of ice-cold Qproteome 
CE3 nuclear/large organelle compartment extraction buffer sup-
plemented with 1× of the kit Protease Inhibitor Solution before 
being tumbled for 10 min at 4°C. The lysate was next clarified by 
centrifugation at 6800 × g for 10 min at 4°C. The supernatant, 
representing the nuclear/large organelle cellular fraction, was 
removed to a fresh Eppendorf tube. The extant cell pellet was 
then solubilized in 250 μl of room temperature Qproteome CE4 
cytoskeletal fraction extraction buffer.
glucose Uptake assays
For specific glucose uptake assessment, cultured cell monolay-
ers were glucose- and serum-deprived in Krebs Ringer buffer 
(25  mM NaCl, 5  mM KCl, 1.25  mM NaH2PO4, 2  mM CaCl2, 
1 mM MgCl2, 25 mM NaHCO3) at 37°C and 5% CO2 for 40 min 
on the day of experimentation. To determine glucose uptake rates, 
the specified glucose bolus dose was added to the Krebs Ringer 
buffer, and 30 μL aliquots were taken at 0, 1, 5, 10, 15 and 30 min. 
Glucose concentration from each aliquot was determined using 
a fluorescent glucose assay kit (# K606-100: BioVision, Milpitas, 
CA, USA) as per manufacturer’s instructions. Cells were lysed at 
the end of the experiment, and protein concentration was deter-
mined through a BCA assay (ThermoFisher Scientific, Waltham, 
MA, USA). Glucose uptake curves were then normalized for each 
experiment against the respective total protein concentration 
measured.
rna extraction and Oligonucleotide 
Microarray hybridization
RNA isolation from three animals in each experimental group 
was carried out using the Qiagen RNeasy Mini Kit (Qiagen, 
Inc., Valencia, CA, USA), as described previously (68). RNA 
conversion to cDNA and subsequent hybridization with Sentrix 
MouseRef-8 Expression BeadChips (Illumina, San Diego, CA, 
USA) was performed as described previously (19, 69). Microarray 
data were analyzed using DIANE 6.09, a spreadsheet-based micro-
array analysis program based on the SAS JMP7.0 system10. Raw 
microarray data were subjected to filtering and z-normalization 
and tested for significant changes as described previously (19). 
Initial filtering identified genes with a z-ratio of ≥ ±1.50, with the 
z-ratio being derived from the difference between the averages of 
the observed gene z-scores divided by the SD of all of the differ-
ences for that particular comparison. Genes were then refined by 
calculating the FDR, which controls for the expected proportion 
of falsely rejected hypotheses, and including only those genes 
with FDR <0.05. These data were further analyzed using analysis 
of variance with significance set at p < 0.05. This allowed us to 
identify transcripts that differed in their intensity across all of the 
animal replicates and the various experimental conditions of the 
mice employed in this study.
statistical analyses
In each histogram or figure, data represent the means ±  SEM. 
Statistical analyses (Student’s t-test) were performed using 
GraphPad Prism (GraphPad Software, San Diego, CA, USA). 
p ≤  0.05 was considered statistically significant. Significance is 
indicated in each figure as *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
resUlTs
loss of giT2 Protein affects Whole-Body 
Metabolic activity independent of Physical 
Motor activity
As metabolic activity has been strongly linked with aging and 
multiple disease processes, we first investigated how genetic 
deletion of the aging-associated factor, GIT2, affected somatic 
metabolism and activity in post-pubertal 4-month-old (m.o.) 
male GIT2KO mice compared to age- and gender-matched con-
trol WT mice (Figure 1). Compared to WT mice, over the 48-h 
CLAMS-assessment period, we found that male GIT2KO mice 
demonstrated significantly lower levels of VO2, VCO2, and con-
sequently RER (Respiratory Exchange Ratio) (Figures  1A–C). 
In addition, we also found that GIT2KO mice demonstrated a 
significantly lower thermal output temperature, compared to 
9 http://www.grc.nia.nih.gov/branches/rrb/dna/dna.htm
10 http://www.sas.com/en_us/home.html
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WT controls (Figure 1D). In contrast to the significant altera-
tions in the aforementioned metabolic parameters, no significant 
differences in physical motor activity (in x total or z axis) across 
the test period between WT and GIT2KO mice (Figures 1E,F) 
were observed, indicating that the metabolic distinctions were 
not due to alterations in physical motor activity. In addition to 
the altered metabolic parameters present in the GIT2KO mice, a 
significant reduction in both food and water intake was observed 
compared to WT controls (Figures 1G,H). GIT2KO mice also 
demonstrated an increased propensity for longer sleep/inactivity 
epochs compared to WT mice (Figure 1I).
Transcriptomic signatures of Metabolic 
Disruption in giT2KO hypothalami
Our whole-body metabolic analyses of the GIT2KO mice 
demonstrated a strong alteration in metabolic activity. We have 
FigUre 1 | Whole-body metabolic analysis of WT and giT2KO mice. Male WT or GIT2KO mice were housed for 48 h in a Columbus Instruments International 
Comprehensive Lab Animal Monitoring System (CLAMS). VO2 (a), VCO2 (B), RER (respiratory exchange ratio) (c), HEAT (ambient heat generation) measurements 
for WT and GIT2KO mice (D). Locomotor physical movement × total activity (e) and z total activity (F) measurements were made for WT and GIT2KO mice. 
Accumulated drinking (g) and accumulated food intake (h) and sleep epochs, total time sleeping, and % of time asleep (i) measurements were also recorded. 
For (a–h), WT datapoints are represented by black circles; GIT2KO datapoints are represented by open triangles. Gray areas in each panel (a–h) indicate the dark 
period of animal incubation. For (i), WT data is indicated by black bars and GIT2KO data by white bars. Statistical significance is indicated in each figure as 
*p ≤ 0.05; **p ≤ 0.01. 
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previously shown that aberrant hypothalamic signaling activity 
(13) as well as transcriptomic profiles (69) are strongly linked to 
both pathological aging as well as the presentation of neurode-
generative disease. We therefore assessed, using microarray, the 
effects of GIT2 genomic deletion on hypothalamic transcrip-
tomic profiles in male mice at 2, 4, and 8 months of age as these 
timepoints encompass our initial CLAMS 4-m.o. timepoint data. 
This timeframe was chosen to represent post-pubertal early life 
periods in which overt age-related damage may not be present 
but signatures of pro-aging behavior may be observed (42). Gene 
transcripts differentially and significantly (p < 0.05) regulated in 
GIT2KO hypothalami compared to age-matched WT mice across 
the three time points were investigated using VennPlex (57) 
(Figure 2A). Surprisingly, we found that transcriptomic profiles 
[Tables S1 in Supplementary Material (2 m.o.), S2 (4 m.o.) and S3 
(8 m.o.)] were strongly age-specific, with a considerable percent-
age of transcripts being uniquely regulated at a single time-point 
(2 m.o. – 88.9% unique; 4 m.o. – 88.6% unique; 8 m.o. – 82.03% 
unique). Across the three experimental ages, we found 46 
transcripts common to at least two timepoints (Figure 2B) – we 
randomly selected four of these transcripts (Pebp1, Reep5, 
Hmgn2, Diablo) to validate, using Western blotting (Figure 2C). 
Our Western blot analysis of hypothalamic tissues replicated our 
microarray-derived transcriptomic regulation patterns in the 
GIT2KO mice. The functional effects of the group of 46 GIT2KO-
modulatated transcripts identified across all timepoints were then 
investigated using unbiased Textrous!-mediated transcript-word 
association (59, 62, 70). Using the collective processing module 
of Textrous! to generate a hierarchical word cloud, a strong focus 
upon neurotransmission and metabolism was evident (Figure 
S1 in Supplementary Material). With extraction of the primary 
word list associated with the 46 input transcripts (Table S4 in 
Supplementary Material), multiple words associated with glucose 
regulation (“insulin,” “proinsulin,” “euglycemic,” “glucose,” “intoler-
ance,” “incretin,” “insulin-responsive,” “c-peptide”) were strongly 
evident. A typical healthy animal using glucose as its primary 
source of energy demonstrates an RER of approximately 1 
(observed in the WT mice: Figure 1C), the GIT2KO mice however 
FigUre 2 | hypothalamic transcriptomic signatures in WT and giT2KO mice across early life span timepoints. (a) Differential VennPlex analysis of 
hypothalamic transcriptomic data from 2-, 4-, and 8-month-old (m.o.) GIT2KO mice compared to age-matched WT controls. Contra-regulation denotes transcripts 
common to at least two Venn sectors that possess a different expression polarity. (B) Transcript z-ratios of significantly regulated transcripts in GIT2KO mice 
(compared to WT controls) common to at least two age timepoints. (c) Western blot validation of selected differentially regulated gene transcripts. WT data is 
indicated by black histogram bars: white histogram bars denote GIT2KO data. (D) Latent semantic indexing-based age-dependent ranking of biological functions 
related to GIT2KO physical and molecular phenotypes. Statistical significance is indicated in each figure as *p ≤ 0.05; **p ≤ 0.01.
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possessed an RER of approximately 0.8 across the testing period 
(Figure 1C), which is suggestive of loss of glucose catabolism in 
favor of lipid metabolism. In line with this a strong representa-
tion of terms linked with lipid metabolism were also found in the 
Textrous! output form the 46 core GIT2KO transcripts (Figure S1 
in Supplementary Material; Table S4 in Supplementary Material), 
e.g., “adipocytes,” “lipolysis,” “fatty,” and “triacylglycerol.”
early aging Pathological Trajectories in 
giT2KO Mice
With the combination of our whole-animal metabolic/behav-
ioral analyses and our transcriptomic profiling of the GIT2KO 
hypothalamic, a strong metabolism-related pathological sig-
nature was evident. Using an analogous informatics process to 
Textrous!, i.e., GeneIndexer (Computable Genomix Inc.), that 
applies LSI to extract transcript-word associations in the reverse 
direction (19, 62), i.e., from input text term to correlated tran-
script, we investigated how pathological metabolic trajectories 
may be evident in the GIT2KO mice even at these early life 2, 4, 
and 8 month timepoints. Therefore, we created lists of implicitly 
associated transcripts, across the three timepoints, linked to 
functional and behavioral aspects we observed in the GIT2KO 
mice, denoted by our input GeneIndexer interrogator terms 
(Table S5 in Supplementary Material; Table S6 in Supplementary 
Material – 2 m.o.; Table S7 in Supplementary Material – 4 m.o.; 
Table S8 in Supplementary Material  –  8  m.o.). To assess the 
relative importance, using the hypothalamic transcriptomic 
datasets (2, 4, and 8  m.o.), of these terms at the specific 
experimental time points, the mean cosine similarity scores 
for the implicitly associated transcripts for each interrogator 
term were calculated. Using these mean cosine similarity score 
magnitudes, we ranked (from term 1 to term 18) the terms at 
each age timepoint – for presentation purposes we reciprocally 
transformed these ranks (Table S9 in Supplementary Material). 
Using this novel informatics approach, it is clear that multiple 
metabolic aspects (“mitochondria,” “diabetes,” “insulin,” “glucose,” 
“electron transfer chain,” “fat,” “energy,” “aging”) demonstrate, at 
these early life timepoints, a coherent age-dependent increase 
(Figure  2D). Interestingly, many of the behavioral factors we 
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observed (Figure 1) that were disrupted (“thirst,” “thermogen-
esis,” “heat,” “sleep”) demonstrated an opposite age-dependent 
ranking mechanism (Figure 2D).
Multidimensional signaling network 
alteration of Metabolic and glycemic 
activity in giT2KO Mice
To complement our novel transcriptomic data investigation 
using LSI-based techniques, we also performed unbiased 
KEGG signaling pathway enrichment analysis on the 2-, 4-, and 
8-m.o. transcriptomic datasets (Table S10 in Supplementary 
Material  –  2  m.o.; S11  –  4  m.o.; S12  –  8  m.o.). Similar to our 
basic transcriptomic analyses, we found that the predicted KEGG 
signaling pathway activity was age-specific, but to a much lesser 
extent than the primary transcripts, i.e., 2 m.o. 60% of pathways 
were unique; 4 m.o. 52% of pathways were unique and for 8 m.o. 
Sixty-five percent of pathways were unique (Figure 3A). In line 
with our CLAMS whole-body analysis and LSI-mediated tran-
scriptomic investigation, the KEGG pathways demonstrating a 
link across the three timepoints (i.e., present in at least two of 
the age timepoints: 17 pathways) possessed a strong focus upon 
energy metabolism (“Metabolic Pathways,” “Purine metabolism,” 
“Synthesis and degradation of ketone bodies,” “Glutathione metabo-
lism”) as well as upon signaling functions associated with GIT2, 
such as cellular trafficking (“Endocytosis”) and DNA damage/
repair (“Nucleotide excision repair”) (Figure 3B). Three pathways 
were common to all three animal ages: “Metabolic Pathways,” 
“Purine metabolism,” and “Huntington’s disease.” We have previ-
ously demonstrated that Huntington’s disease is often associated, 
in patients and especially in transgenic murine models of the 
disease, with considerable glycemic and metabolic dysfunc-
tion linked to pancreatic morphology alteration and diabetic 
pathological phenotypes (53, 54, 71, 72). Therefore, this signaling 
pathway data reinforces the potential for GIT2 deletion to induce 
a systemic glycemic/metabolic disruption linked to central and 
peripheral degenerative actions. With respect to this pathologi-
cal link, we chose to further investigate the high-dimensionality 
molecular metabolic phenotype of the GIT2KO mice using our 
KEGG data from the 8 m.o. timepoint as this age demonstrated the 
greatest linkages to glycemic/metabolic alterations (Figure 2D). 
Using our previously demonstrated KEGG signaling pathway-
based keystone discovery workflow (13), we created an LSI-based 
pathway-transcript matrix (0.67 × 106 total cell size: Figure 3C; 
Table S13 in Supplementary Material). From this matrix, we 
identified the 99% class percentile most cross-KEGG pathway 
conserved gene transcripts (92 in total: indicated in italic – Table 
S13 in Supplementary Material, Figure  3D-expanded view 
of top of heatmap in Figure  3C, Figure  3E-color-coded 99% 
percentile transcript identification). For illustration purposes, 
the top 30 cross-KEGG pathway correlated transcripts are indi-
cated (Figures  3D,E). Many of the 92 transcripts identified in 
the 99% percentile of cross-KEGG pathway group are critically 
involved in metabolic activities linked to diabetes-related patho-
physiologies, e.g., Cox2 [cytochrome c oxidase subunit II (73)], 
Coasy [CoA synthase (74)], and Akt2 (75). Textrous!-based 
interpretation of this 92 “keystone” transcript dataset, using 
the individual processing mode [Figure  4A (59)], revealed a 
strong link to glycemic regulation (“glucose-dependent,” “insulin,” 
“glycolysis,” “amp-activated”) and insulin functionality (“incretin,” 
“hyperglycemia,” “insulinotropic”). Using the ability of Textrous! 
to extract scientifically relevant noun-phrases linked to the input 
transcripts (62), we created a “higher-order” word cloud using 
Wordle11 from these semantically associated nouns and noun-
phrases (3773 input words in total: Figure 4B). This word cloud 
again underscored the importance of insulin-related glycemic 
regulation in GIT2KO mice compared to WT controls. Using the 
web-based phrase frequency counter suite of WriteWords12, we 
were able to extract from the input nouns and noun-phrases, the 
most common phrases of various word lengths (Figures 4C–H). 
Using this unbiased dataset description technique, we found 
sentences describing “DNA damage repair,” “fatty acid oxidation,” 
“mitochondrial activity,” and “ROS” were prominent – thus again 
confirming a functional intersection between metabolic actions 
and GIT2-related functionality [e.g., DNA repair and ROS 
responsivity (18, 19)]. As we have consistently found a strong cor-
relation between GIT2 genomic deletion and global metabolism 
disruption (Figure 1), predicted insulin/glucose system disrup-
tion (Figures 2–4) and potential pancreatic pathology (Figure 2), 
we next assessed whether GIT2 genomic deletion affected the 
functional morphology of the murine pancreas.
genomic Deletion of giT2 Disrupts 
Pancreatic Morphology
Histochemical analysis of isolated pancreatic islets from control 
WT mice demonstrated a strong reactivity with GIT2 antibod-
ies in pancreatic islet-like structures (Figure 5A, inset B). With 
differential histochemical staining for GIT2, insulin (for beta 
cells), or glucagon (for alpha cells), it was evident that GIT2 was 
present in both alpha and beta cells of the pancreatic islets (GIT2: 
Figures 5C–E, glucagon: Figures 5F–H). Using our previously 
described islet analytical workflow (55), we found that 8-m.o. 
GIT2KO mice demonstrated a significantly reduced islet area 
(Figure 5I) and beta cell percentage (Figure 5J) with a concomitant 
significant increase in alpha cell percentage (Figure 5K). Linked 
to these data, we also found a significant increase in the total 
alpha cell area (Figure 5L), again with an expected reduction in 
total beta cell area (Figure 5M). Using our islet size differentiation 
parameters, we also found a general increase in the numbers of 
smaller islets in GIT2KO compared to WT controls (Figure 5N). 
Performing similar analysis on 2- and 4-m.o. GIT2KO mice, we 
found that while differences in pancreatic morphology compared 
to WT mice were evident, none however were significant (Figure 
S2 in Supplementary Material). Using visual morphological 
inspection of the 8-m.o. GIT2KO islets, it was clear that along 
with the decrease in beta cells and increase in alpha cells there was 
also an evident alpha cell involution into the beta cell mass – a 
facet indicative of diabetic pathologies in murine paradigms [WT 
mice: Figures 5O–Q, GIT2KO mice: Figures 5R–T (76, 77)]. This 
11 http://www.wordle.net/
12 www.writewords.org.uk/phrase_count.asp
FigUre 3 | Kegg signaling pathway-based keystone analysis of giT2KO hypothalamic signatures. (a) Differential VennPlex analysis of hypothalamic 
KEGG signaling pathway data generated with the primary microarray transcriptomic data from 2-, 4-, and 8-month-old (m.o.) GIT2KO mice compared to 
age-matched WT controls. (B) Probability ranking scores for KEGG signaling pathways common to at least two different experimental age timepoints. #denotes 
KEGG pathways significantly populated by transcriptomic data from all three experimental timepoints. (c) KEGG pathway-generated cosine similarity score matrix 
generated using latent semantic output from GeneIndexer. Thirty two separate columns representing each significantly regulated KEGG pathway from the 8-m.o. 
hypothalamic microarray data were used to create the matrix of implicitly linked transcripts. Only transcripts demonstrating a correlation to at least two KEGG 
pathways were considered for analysis. Each level of transcript association (from 2 to 32 KEGG pathways) is indicated by a selective heatmap color (matrix 
size = 0.67 × 106 cells: top and bottom of matrix are labeled). (D) Expanded inset of top 30 most highly correlating matrix transcripts across the 32 KEGG 
pathways. (e) Class-based identification of the 92 transcripts within the 99% percentile of cross-pathway correlation probability.
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FigUre 4 | natural language processing-based analysis of multidimensional giT2KO molecular pathway signatures. 
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(a) Textrous!-based individual processing heatmap processing of the core 92 transcripts represented in Figure 3 comprising the multidimensional GIT2KO pathway 
signature. The strength of noun-transcript correlation is indicated by the intensity of teal color of the block. (B) Higher-order word cloud representation of expanded 
noun and noun-phrase output from the individual processing analysis in (a). The size of the resultant noun is indicative of the frequency in the output. (c–h) Textual 
phrase analysis (WriteWords*) of the higher-order word cloud data using length-dependent [(c) – two words, (D) – three words, (e) – four words, (F) – five words, 
(g) – six words, (h) – seven words] sentence analysis. Within each panel (c–h) the relative phrase frequencies is indicated relatively by the phrase text size.
* http://www.writewords.org.uk/
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involution was generally absent in both 2-and 4-m.o. GIT2KO 
mice (Figure S3).
genomic Deletion of giT2 Disrupts Plasma 
Membrane Metabolic hormone levels and 
Pancreatic Functionality
To further investigate the systemic metabolic effects of genomic 
GIT2 deletion, we measured the levels of multiple metabolic 
hormones [insulin, amylin, leptin, GIP (gastric inhibitory 
polypeptide), PP (pancreatic polypeptide), PYY (peptide YY)] in 
8-m.o. GIT2KO mice compared to WT controls (Figures 6A–F). 
Deletion of GIT2 resulted, at the 8-m.o. timepoint, in significant 
reductions in plasma insulin, amylin, and PYY along with a 
significant increase in the PP levels. Significant age-dependent 
reductions of insulin were observed at the 2- and 4-m.o. timepoints 
(Figure S4): trends for non-significant reductions in both amylin 
and leptin where observed (Figure S4) as were non-significant 
increases in plasma GIP (Figure S4). Consistent with the multiple 
molecular glycemic pathologies observed in the GIT2KO mice, 
we found that as early as 4 months of age (and continuing onto 
8 m.o.), a significantly higher fasting plasma glucose was evident 
compared to age-matched WT controls (Figure 6G). We investi-
gated whether this elevated plasma glucose was associated with 
a reduction in the insulinotropic functionality of GIT2KO mice. 
Using a standard ITT approach, we found that the 8-m.o. GIT2KO 
demonstrated a significant degree of insulin resistance to a bolus 
dose of Lantus® (Figure 6H). Therefore, along with the disruption 
of beta cell mass, alpha cell involution, and reduced plasma insulin 
levels the GIT2KO mice also demonstrate significant insulin 
resistance. Performing standardized OGTT analysis, we also 
found that GIT2KO mice (at 8 m.o.) demonstrated a significantly 
lower ability to uptake a glucose bolus (Figure 6I). Coordinating 
with this reduced glucose uptake ability, we found that GIT2KO 
mice possessed a significantly diminished capacity to functionally 
secrete insulin in response to the glucose bolus (Figure 6J).
high-Dimensionality Transcriptomic 
Profiling of giT2KO Pancreatic islets
From our metabolic, behavioral, informatic, and hormonal 
analyses, a clear disruption of pancreatic function in GIT2KO 
mice is evident. We chose to study this at a high-dimensionality 
level, using quantitative transcriptomics on mechanically 
isolated islets from 8-m.o. GIT2KO mice. Using purified islets 
from multiple GIT2KO or WT (n ≥  3) mice, a differentially 
regulated transcriptomic profile was generated (Table S14 in 
Supplementary Material). At the basic transcriptomic level 
multiple transcripts closely linked to diabetic pathology and islet 
dysfunction were differentially regulated in GIT2KO compared 
to WT islets, e.g., Slc2a2 [glucose transporter 2 (78)], Reg3a/b 
[regenerating islet-derived protein 3 alpha/beta (79)], Ffa2 [free 
fatty acid receptor 2 (80)], Trib3 [tribbles homolog 3 (81)], 
PP [pancreatic polypeptide (82)], Sesn1 [sestrin 1 (83)], Glo1 
[glyoxylase 1 (84)], and Lars2 [leucyl-tRNA synthetase 2, mito-
chondrial (85)]. Using “pancreas-specific” tissue database signal-
ing investigation with IPA, we applied Disease/Bio-Function 
annotation to the GIT2KO islet transcriptome data (Table S15 in 
Supplementary Material). Corroborating our histochemical and 
functional pancreatic data, we found several prominent beta-cell 
focused functions (e.g., “development of pancreas,” “abnormal 
morphology of pancreas,” “abnormal morphology of beta islet cells”) 
within this unbiased analysis output (highlighted in Figure 7). 
To complement our Disease/Bio-Function annotation, we also 
assessed the most coherently associated functional networks 
within the GIT2KO transcriptomic data. The two highest scor-
ing networks (based on numbers of enriched transcripts from 
the input data that form a coherent-curated network) focused 
on Scl2a2-Hnf4a-Hnf1a (Figure S5 in Supplementary Material) 
and Pdx1-Ins1-Glis3 (Figure S6 in Supplementary Material) were 
both officially (via IPA) denoted as involved in “Cell Death and 
Survival – Endocrine System Disorders – Metabolic Disease.” As 
several well-characterized murine pancreatic beta cell clonal lines 
exist, e.g., Beta-TC-6 (ATCC: abbreviated to “TC-6” hereafter), 
we decided to orthogonally investigate the link between GIT2 
and several factors identified in our transcriptomic analysis using 
siRNA-mediated depletion of GIT2 followed by selective Western 
blot analysis (Figure 8), using the extracellular signal-regulated 
kinase 2 (Erk2) as a specific, well-characterized protein-gel 
loading control (86, 87). Using in  vitro siRNA-mediated GIT2 
depletion (50–400  nM siRNA: Figure  8A), we were able to 
significantly attenuate the expression of GIT2 in the TC-6 cells. 
Employing the 400 nM concentration of level of GIT2 siRNA to 
reduce cellular GIT2 levels, we were able to recapitulate selected 
expression data generated from our microarray analysis, with 
specific relevance to beta cell function, metabolism, diabetes, 
and aging (Table S15 in Supplementary Material: Figures 8B–I). 
Hence acute siRNA; mediated reduction of cellular GIT2 caused 
increased expression of Dcx [doublecortin, Figure 8C (88)], Glo1 
[glyoxylase I, Figure 8D (89)], Ndufb10 [NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex subunit 10, Figure 8E (90)) as 
well as a decreased expression of Mrpl12 [mitochondrial ribo-
somal protein L12, Figure  8F (91)], Atm [ataxia telangiectasia 
mutated, Figure  8G (18)], Reg3b [regenerating islet-derived 3 
beta, Figure 8H (92)], and Sesn1 [sestrin 1, Figure 8I (93)].
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giT2 Functionality in Murine Pancreatic 
Beta cells
From our transcriptomic and functional analyses, it is evident 
that GIT2 integrity is important in regulating insulin sensitivity 
and beta cell function. We next investigated the molecular nature 
of GIT2 activity, related to glycemic control, in beta cells using 
the TC-6 murine model cell line. As the GIT2KO mice demon-
strate insulin resistance, we mimicked this pathophysiological 
state in the TC-6 cells by chronic (24 h) treatment with palmitic 
acid (94). In response to palmitic acid exposure, we found both 
increases in Glut2 as well as GIT2 (Figure  9A), here again we 
employed the extracellular signal-regulated kinase 2 (Erk2) as a 
specific, well-characterized protein gel loading control (86, 87). 
Extension of the chronic exposure to 4  days (10  μM palmitic 
acid – replenished every 6 h) demonstrated that the GIT2 expres-
sion was subsequently attenuated while the Glut2 potentiation 
FigUre 5 | genomic giT2 deletion affects pancreatic islet functional structure. (a) DAB- (3,3′-diaminobenzidine) based immunohistochemical identification 
of GIT2-associated reactivity in discrete islet-like structures in WT murine pancreas. (B) High-magnification inset of DAB-stained, GIT2-immunoreactive pancreatic 
islet-like structure. (c) GIT2 AF488 immunostaining of WT pancreatic islet. (D) Glucagon AF568 immunostaining of WT pancreatic islet. (e) Merge of panels  
(c,D) indicating AF488–AF568 colocalization. (F) Insulin AF488 immunostaining of WT pancreatic islet. (g) GIT2 AF568 immunostaining of WT pancreatic islet.  
(h) Merge of panels (F,g) indicating AF488–AF568 colocalization. MATLAB-based pancreatic islet mathematical automated assessment of WT (black bars) or 
GIT2KO (white bars) pancreas islet area (i), β-cell percentage (J), α-cell percentage (K), α-cell area (l), β-cell area (M) and islet number/size distribution (n).  
(O) Insulin AF488, glucagon (P) immunostaining of WT islet [8 month old (m.o.)]. (Q) Merge of panels (O,P). (r) Insulin AF488, glucagon (s) immunostaining of 
GIT2KO islet (8 m.o.). (T) Merge of panels (r,s). Statistical significance is indicated in a specific panel as *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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persisted, mimicking our mouse model paradigm of GIT2KO 
status with an elevation of beta cell Glut2/Slc2a2 (Table S15 in 
Supplementary Material; Figure  9B). We assessed the viability 
of the TC-6 cells in response to extended palmitate treatments 
using Trypan Blue exclusion cell counting and failed to demon-
strate any significant loss of viability compared to actinomycin 
D-treated (2 μg/ml, 2-h exposure) positive controls (Figure S7 in 
Supplementary Material). In this in vitro experimental system, we 
then assessed the ability of the palmitic acid-treated cells to uptake 
glucose. Performing an in vitro glucose uptake assay using 5 mM 
glucose (19), we found that cells possessing a diminished GIT2 
in the presence of elevated Glut2 have an attenuation of glucose 
uptake capacity compared to non-treated cells (Figure 9C). Using 
Q-proteome®-based subcellular fractionation of these palmitic 
acid-treated cells (4 days treatment), we found that in response 
to the introduction of the glucose bolus, the pre-treatment of cell 
with palmitic acid significantly affected the glucose-induced sub-
cellular redistribution of GIT2 (Figure 9D). Appropriate subcel-
lular fractionation of the cellular samples with the Q-proteome® 
system was assessed using specific western blots for marker pro-
teins characterized by cytoplasmic (Gapdh), plasma membrane 
(Pmca), nuclear/large organelle (Lmna), or cytoskeletal (Tuba1a) 
expression (Figure S8 in Supplementary Material). In control 
cells, GIT2 immunoreactive signals increased in the cytoplasmic 
and plasma membrane fractions in response to the glucose dose. 
This increase, in both cytoplasmic and plasma membrane com-
partments, was significantly attenuated in the palmitate-treated 
cells. No significant dynamic changes in GIT2 immunoreactive 
signals were observed in the nuclear fractions, however an eleva-
tion of basal nuclear GIT2 was observed in the palmitate-treated 
cells (Figure  9D). This effect is likely caused by the metabolic 
stress of chronic palmitate treatment causing ROS damage as 
we have previously demonstrated that multiple cellular stressors 
promote GIT2 nuclear translocation to regulate the DNA damage 
response (18). These data therefore suggest that molecular attenu-
ation of GIT2 affects glucose sensitivity of beta cells and cellular 
GIT2 redistribution is important for cellular functions such as 
glucose uptake. In line with these findings, we also noted that 
FigUre 6 | giT2 genomic deletion affects multiple circulating energy-regulatory factors and response to external glycemic challenges. Differential 
circulating plasma levels of insulin (a), amylin (B), leptin (c), GIP [gastric inhibitory peptide: (D)], PP [pancreatic polypeptide: (e)], and PYY [peptide YY: (F)] between 
8-m.o. (month old) WT (black bars) and GIT2KO (white bars) mice. (g) Fasting blood glucose measurements for 2-, 4-, 8-m.o. WT (black bars) or GIT2KO (white 
bars) mice. For (h–J) WT or GIT2KO mouse data is represented by black circles or open triangles respectively. (h) Standard bolus insulin tolerance test (ITT: 0.5U/
kg insulin) performed on 8-m.o. WT or GIT2KO mice. (i) Time-dependent elevation of plasma glucose in 8-m.o. WT or GIT2KO mice after intragastric introduction of 
a glucose bolus (2g/kg). (J) Time-dependent elevation of plasma insulin in 8-m.o. WT or GIT2KO mice after intragastric introduction of a glucose bolus (2 g/kg). For 
each experimental panel, statistical significance is indicated in each figure as *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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siRNA-mediated partial GIT2 depletion engendered a consistent 
but moderate (non-significant) attenuation of glucose uptake in 
TC-6 cells (Figure S9 in Supplementary Material). As GIT2 was 
first identified as a GPCR-associated scaffolding protein (95), its 
functions are typically mediated via assembling and regulating the 
composition of multiprotein complexes. Therefore, using selective 
immunoprecipitation in control, non-diabetic, and pathophysi-
ological conditions from whole pancreas, we next investigated the 
nature of its physical molecular interactions in these paradigms.
Pathological Metabolic alteration of 
giT2 interaction Partners
As GIT2 genomic deletion induces a strong metabolic phenotype 
to appreciate the effects of metabolic stress upon GIT2 function-
ality, we next investigated the potential functional interaction 
partners of GIT2 in pancreatic tissue from experimental animals 
experiencing significant metabolic stress, i.e., diabetic db/db mice 
(55, 96). Db/db mice possessing a mutation in the leptin receptor 
demonstrate an increased propensity for diet-induced obesity and 
diabetes via congenital hyperphagia (97). Upon inspection of the 
GIT2 expression levels in 8-m.o. WT control and db/db mice, in both 
the hypothalamus and pancreas GIT2 expression was significantly 
elevated on db/db mice compared to the controls (Figure 10A). 
Therefore, in a pro-diabetic state, GIT2 expression is elevated, sug-
gesting that GIT2 expression is not only age- and stress-sensitive 
(13, 18, 19), but also sensitive to the alteration of “metabolic” age in 
the db/db model (42, 98–100). To identify the effects of diabetes-
related pathology on GIT2 protein–protein complex interactions, 
we performed selective GIT2 co-immunoprecipitation (co-IP) 
(with pre-immune sera as a negative control) in WT and db/db 
pancreatic cell lysates (Figure 10B). Due to the elevation of GIT2 
expression in db/db samples (Figures 10B,C), we normalized for 
GIT2 content of the co-IP samples used for subsequent Western 
blotting or MS analysis. Investigation of extracted and digested 
GIT2 co-IP samples with our linear ion trap LC-MS/MS identi-
fied 170 specific co-precipitating proteins from WT pancreatic 
lysates (Table S16 in Supplementary Material) and 153 specific 
co-precipitating proteins from db/db pancreatic lysates (Table 
S17 in Supplementary Material). The majority of these proteins 
were conserved (65%) between WT and db/db co-IP extractions 
(Figure 10D). However, it was interesting to note that within the 
proteins found only in the WT venn sector, i.e., lost with metabolic 
dysfunction, multiple glycemic-related factors were evident (Table 
S18 in Supplementary Material), e.g., the insulin receptor (Insr), 
insulin receptor substrate 2 (Irs2), fatty acid binding protein 2 
[Fabp2 (101)], signal sequence receptor delta [Ssr4 (102)] and G 
protein-coupled receptor 101 [Gpr101 (103)]. In addition to these 
WT-specific metabolic factors, it was also evident that additional 
proteins within the WT-only venn sector were associated with 
other activities strongly implicated in pathological aging including 
molecular aging, DNA damage and stress, e.g., structural main-
tenance of chromosomes 5 [Smc5 (104)], eukaryotic translation 
initiation factor 2B [Eif2b2 (105)], negative regulator of ubiquitin-
like proteins 1 [Nub1 (106)], and DEAD (Asp–Glu–Ala–Asp) 
box helicase 3, X-linked [Ddx3x (107)]. We validated our MS 
data using selective Western blotting for several of the GIT2 co-
precipitating factors unique to WT or db/db tissues (Figure 10E). 
Hence, we found a reduced association between GIT2 and Insr, 
Irs2, and Smc5 in the db/db samples. In contrast, we found an 
increased association between GIT2 and Rpl17 (ribosomal protein 
L17), Fau/MNSFβ (Monoclonal non-specific suppressor factor β), 
FigUre 7 | Disease Bio-Function analysis of pancreatic islet transcriptomic data. Significant transcriptomic data from isolated GIT2KO pancreatic islets 
was functionally annotated using the Disease/Bio-Function suite from IPA Pathways Analysis. The regulation of three processes vital for pancreatic function is 
indicated: “development of pancreas, ‘abnormal morphology of pancreas,’ abnormal morphology of beta islet cells.” The nature of the specific node components 
and their type of functional interaction (noted as arrows between factors) are described in the associated key. Red factors were upregulated in the input dataset 
while green factors were downregulated (GIT2KO versus WT).
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and Fbxo24 (F-Box Only Protein 24/IKK1) in the pathological db/
db state. Interestingly, both Fau/MNSFβ and Fbxo24 are associated 
with apoptotic activity linked to inflammation and DNA damage 
(108, 109). Proteins commonly co-precipitating with GIT2 in 
both WT and db/db conditions (Map1a, Pdrg1, Caskin2) were 
also validated and were found to equally associate with GIT2 in 
both conditions (Figure 10D). In addition to the investigation of 
individual GIT2 protein–protein complex interactions, we also 
investigated the potential cell signaling ramifications of these 
multiple associations. Using both KEGG (WT mice: Table S19 in 
Supplementary Material, Table S20 in Supplementary Material: 
db/db mice) and IPA Canonical Signaling Pathway analyses 
(WT mice: Table S21 in Supplementary Material, Table S22 in 
Supplementary Material: db/db mice) of the respective co-IP 
datasets we again demonstrated a strong distinction between 
the functional links of GIT2-associated proteins in control WT 
conditions compared to db/db (Figures 10F,G). Inspection of the 
selective WT-unique signaling pathways (Figures 10E,F) revealed 
a strong link of GIT2-associated proteins with energy regulation 
(“Type II diabetes mellitus signaling,” “Fat digestion and absorption,” 
“PPAR signaling pathway,” “Maturity Onset Diabetes of Young 
(MODY) Signaling,” “AMPK Signaling”), cellular development 
(“Notch signaling”) and degenerative diseases linked to metabolic 
dysfunctions [“Huntington’s disease,” “Amyotrophic lateral sclerosis 
signaling” (53, 110)]. As expected from the scaffolding nature 
of GIT2 and its well-characterized role in cytoskeletal regula-
tion (111), a strong representation of such factors was evident 
(Figures 10E,F: “Regulation of actin cytoskeleton,” “Focal adhesion,” 
“Actin Cytoskeleton Signaling”).
DiscUssiOn
Given the inevitable worldwide rise in the incidence of age-related 
disorders, it is imperative that a more nuanced understanding of 
the systemic control of the multiple processes that underpin aging 
is developed. Intensively complex, multidimensional events such 
as whole somatic aging are likely to be coordinated by a series 
of differential protein hierarchies, in which lower-dimensionality 
protein functions, e.g., simple mitogen-activated protein kinase 
(MAPK) cascades are orchestrated and connected to other linear 
pathways by master-controlling “keystone” or “hub” proteins (13). 
Experimental research into the potential molecular interactions 
that regulate aging across an organisms life span quickly engen-
ders signaling complexity issues comparable to the mathematical 
difficulties of optimally solving NP-hard (Non-deterministic 
Polynomial-time hard) or NP-complete calculations (112, 113). 
FigUre 8 | Depletion of giT2 in murine pancreatic Tc-6 cells modulates the expression of multiple proteins involved in stress management and 
energy regulation. (a) Dose-dependent GIT2 depletion curve for GIT2 siRNA. A random sequence “scramble” siRNA was employed as a negative control. 
Extracellular signal-regulated kinase 2 (Erk2) was employed as a loading control throughout this figure. GIT2 siRNA-mediated (using 400 nM siRNA concentration) 
modulation of TC-6 cells expression of GIT2 (B), doublecortin [Dcx: (c)], glyoxylase 1 [Glo1: (D)], NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10 
[Ndufb10: (e)], mitochondrial ribosomal protein L12 [Mrpl12: (F)], ataxia telangiectasia mutated [Atm: (g)], regenerating islet-derived 3 beta [Reg3b: (h)] and sestrin 
1 [Sesn1: (i)]. Statistical significance is indicated in each figure as *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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Therefore, a more pragmatic approach to the investigation of 
hyper complex signaling architectures, both for mechanistic 
knowledge and for eventual therapeutic manipulation of highly 
complex systems, is to identify the central coordinators of these 
complex systems. We have previously illustrated a mechanism 
for uncovering such “keystone” regulatory factors [also known 
as “hub” proteins (114) using our combinatorial bioinformatics 
approach (13)]. Performing such an analysis with primary protein-
based data, extracted from different aged samples of an endocrine 
organ thought to house the regulatory machinery of aging, i.e., 
the hypothalamus (24), we identified the GPCR-interacting pro-
tein GIT2 as a “keystone” of the aging process. Subsequently we 
demonstrated that this protein forms a link between age-related 
cellular damage (ROS, ionizing radiation) and the maintenance of 
DNA repair/stability – a process crucial to successful and healthy 
aging (18). Genomic deletion of GIT2 resulted, with respect to the 
presence of accumulated DNA damage, in accelerated aging of 
murine CNS tissue. As the age-dependent development of insulin 
resistance and the deterioration of glucose-focused oxidative 
phosphorylation efficiency contribute significantly to accelerated 
aging mechanisms, we sought to investigate the potential role 
of GIT2 in systemic metabolic regulation. Using whole-somatic 
metabolic chamber analysis, we found that GIT2KO mice 
demonstrate a significantly reduced RER at a relatively young 
(4 months) age indicating a switch away from glucose use toward 
adipose and then, potentially, protein to generate usable energy 
(Figure  1). Upon investigation of the hypothalamic transcrip-
tomic profiles in GIT2KO mice at younger and older ages (2 and 
FigUre 9 | Pathological manipulation mimicking insulin resistance in murine Tc-6 cells affects giT2 functionality and subcellular disposition. 
Treatment (1 day) of TC-6 cells with palmitic acid (10 μM) and mimicking an insulin-resistant cellular status potentiates GIT2 and Glut2 expression (a). Long-term 
palmitic acid treatment (2–4 days) differentially and biphasically regulates GIT2/Glut 2 expression (B). Extracellular signal-regulated kinase 2 (Erk2) was employed as 
a loading control in (a,B). Attenuation of bolus (5 mM) glucose uptake in TC-6 cells by long-term (4 days) palmitic acid treatment (c). Palmitic acid treatment 
(4 days) of TC-6 cells affects glucose-driven subcellular redistribution of GIT2 across the cytoplasmic, plasma membrane, and nuclear microdomains (D). Statistical 
significance is indicated in each figure as *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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8 months old respectively), we uncovered, using multiple bioin-
formatics techniques, a core transcriptomic “signature” linked to 
metabolic/glycemic regulatory activity (Figure  2D, Figure S1). 
We further reinforced this observation using classical pathway 
annotation pipelines (KEGG pathway analysis: Figure 3) as well 
as novel natural language processing-based investigations using 
the hypothalamic transcriptomic data (Figures 3 and 4). In these 
highly nuanced data outputs, a strong intersection between clas-
sical GIT2 functions (endocytosis and cytoskeletal organization; 
Figures 3 and 4) (111), novel functions (DDR; Figure 4) (18), and 
metabolic activity (glucose, mitochondrial, insulin, and fatty acid 
oxidation: Figure 4) was evident. Given the multiple indications 
of an important role of GIT2 in glycemic regulation, we investi-
gated a potential direct impact of GIT2 in pancreatic tissues that 
secrete insulin and related metabolic factors. We found that GIT2 
was expressed in pancreatic alpha and beta islet cells and that 
genomic deletion in GIT2KO mice resulted in a disruption of 
both beta and alpha cell distribution in the islets. Reinforcing the 
potential for GIT2 to act as a neurometabolic controller, we also 
found moderately diminished levels of the GIT2-associaciated 
signaling factors Pak1 (p21 activated kinase 1) and beta-PIX 
(Arhgef7, Rho guanine nucleotide exchange factor 7) in both 
FigUre 10 | Pathological metabolic status directly affects giT2 expression. (a) Advanced metabolic stress, independent of chronological age, potentiates 
GIT2 expression in hypothalamic and pancreatic tissues. (B) Selective immunoprecipitation of GIT2 (using pre-immune IgG as a negative control) from WT or db/db 
pancreatic whole-cell lysates. Coomassie staining of lysates is employed to indicate equal protein input for immunoprecipitation experiments. (c) Normalization of 
immunoprecipitated GIT2 from pancreatic lysates to adjust for db/db-induced elevation of GIT2. Normalized GIT2 co-immunoprecipitation extracts were then used 
for further semi-quantitative Western blot or mass spectrometry (MS) analysis. (D) Proportional Venn diagram analysis of the protein compositions of GIT2 
co-immunoprecipitates from WT (solid line) of db/db (dashed line) pancreatic lysates. (e) Western blot validation of MS-identified GIT2-associating partners in WT 
and db/db pancreatic tissue lysates. WT data is indicated by black bars while db/db data is represented by white bars. (F) Proportional Venn diagram analysis of 
KEGG pathways significantly populated by GIT2 co-immunoprecipitation data from either WT (solid line) or db/db (dashed line) pancreatic lysates. The associated 
pie chart indicates the relative KEGG pathway hybrid scores [(−log10 (enrichment probability)) × enrichment ratio] for the 16 KEGG pathways unique to the WT 
dataset. Pathways related to metabolism, cytoskeletal signaling and disease are highlighted in bold. (g) Proportional Venn diagram analysis of IPA Canonical 
Signaling pathways significantly populated by GIT2 co-immunoprecipitation data from either WT (solid line) or db/db (dashed line) pancreatic lysates. The associated 
pie chart indicates the relative Canonical pathway score enrichment probabilities (−log10 transformed) for the 15 Canonical Signaling pathways unique to the WT 
dataset. Pathways related to metabolism, cytoskeletal signaling and disease are highlighted in bold. Statistical significance is indicated in each figure as *p ≤ 0.05; 
**p ≤ 0.01; ***p ≤ 0.001.
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GIT2KO hypothalamus and the pancreas compared to WT con-
trols (Figure S10 in Supplementary Material). Arhgef7 has been 
demonstrated to play a role in insulin secretion via regulation of 
Cdc42 (cell division control protein 42 homolog) activity (115). 
In addition the downstream GIT effector Pak1, through physical 
binding and eventual phosphorylation, can control the activity of 
phosphoglucomutase 1, an important regulatory enzyme in cel-
lular glucose utilization and energy homeostasis (116). In pancre-
atic β-cells, Pak1 is also involved in insulin granule localization 
and vesicle release (117), as well as playing a role in pancreatic cell 
development and incretin generation (118).
At the gross pancreatic histological level the GIT2KO mice 
effectively demonstrated (primarily at 8 m.o.) a classical alpha-
cell involution of the insulin-secreting beta cell mass (Figure 5) 
(77). This was accompanied by reductions in circulating levels 
of insulin, amylin, leptin, and peptide YY in 8-m.o. GIT2KO 
mice compared to WT controls (Figure 6). These multiple pan-
creatic alterations were associated with elevated fasting blood 
FigUre 11 | Multifactorial functionality of giT2 in the neurometabolic axis. From our data presented here and from previous research it is becoming clear 
that GIT2 likely acts as a keystone or hub protein for many physiological or cellular signaling processes involved in the maintenance of homeostatic metabolic 
function across life span. To illustrate the multidimensional functionality of GIT2 in such a complex system we have selected proteins/transcripts identified in this 
manuscript to highlight the network-level functional signature of GIT2 activity. The ability of GIT2 to simultaneously control and integrate proteins involved in GPCR 
signaling/trafficking (Adora2b, adenosine A2b receptor; Kdelr2, Lys–Asp–Glu–Leu ER lumen protein retaining receptor 2; Rgs5, regulator of G-protein signaling 5; 
Ramp1, receptor activity-modulating protein 1), insulin receptor (InsR) associated signaling (Irs2, insulin receptor substrate 2; Reg3b, regenerating islet-derived 3 
beta; Insig 2, Insulin induced gene 2; Sesn1, sestrin 1), metabolite/vesicular transport (Glut2, glucose transporter 2; Rims3, regulating synaptic membrane 
exocytosis 3; Slc2a13, solute carrier family 2 (facilitated glucose transporter), member 13; Gltp, glycolipid transport protein), DNA damage repair (DDR) (Atm, 
ataxia-telangiectasia mutated; Wrn, Werner syndrome ATP-dependent helicase; Gadd45a, growth arrest and DNA-damage-inducible protein GADD45 alpha; Parp2, 
Poly (ADP-ribose) polymerase 2), cytoskeletal remodeling (Vim, vimentin; Flna, filamin A; Spnb3, spectrin beta-3; Als2, Alsin) and energy metabolism (Pebp1, 
phosphatidylethanolamine binding protein 1; Glo1, glyoxylase 1; Mfn1, mitofusin 1; Gde1, glycerophosphodiester phosphodiesterase 1) clearly demonstrates 
keystone functionality of GIT2 in neurometabolic aging. Therefore the modulation of the expression of this protein, its post-translational and subcellular distribution 
are likely to strongly influence the orchestration of these vital functions in both health and pathophysiology.
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glucose, insulin (Figure  6), and oral glucose tolerance and a 
diminished insulin secretion capacity in response to glucose 
stimulation (Figure  6). We further reinforced the validity of 
these findings via a high-dimensionality transcriptomic investi-
gation of isolated GIT2KO pancreatic islets. Using IPA Disease/
Bio-Function analysis of the islet data, a strong unbiased dem-
onstration of beta cell developmental disruption was revealed 
(Figure 7). Using murine beta cell culture models, we also found 
that the functional activity of GIT2 in these cells was disrupted 
by cellular stress that mimics insulin resistant pathophysiology 
(Figure 9), i.e., palmitate treatment. While representing a com-
monly employed experimental process (119–122), it is highly 
likely that palmitate-induced insulin resistance is a complex 
multifactorial process that can involve multiple collateral sign-
aling systems effects including altered ceramide levels (123), 
endoplasmic reticulum stress (124), mTOR/S6K activation 
(125), activation of protein phosphatase 2A (126), modulation 
of TNF-α signaling (127), and alterations in transmembrane 
free fatty acid receptor activity (128–130). It is interesting to 
note however, with specific respect to the functional intersection 
between insulin resistance and the aging process, Nakamura 
et al. (131) suggested that palmitate-induced insulin resistance 
in their model was strongly associated with mitochondrially 
derived ROS, a pathological process that is considered one of 
the hallmarks of aging (132). Linked to this it is therefore not 
surprising that in addition to its elevation in aging (13), GIT2 
expression is enhanced by both direct oxygen radical exposure 
(19) and here in our current research with palmitate treatment. 
In line with the interconnection between aging and metabolic 
paradigms we subsequently demonstrated that in the db/db 
pathological paradigm GIT2 was prematurely upregulated 
compared to WT control mice, both in the hypothalamus and 
pancreas (Figure 10). In addition, we found in pancreatic tis-
sues that the physical association of GIT2 with proteins involved 
in the glucose metabolic/insulin-regulatory system, e.g., insulin 
receptor and insulin receptor substrate 2, were disrupted in the 
db/db pathological state (Figure 10). With respect to the large 
number of potential GIT2-associating factors identified in our 
MS experiments, it is interesting to note that multiple interac-
tome databases have already empirically identified well over 
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50 different partners, e.g., BioGRID reports 59 different GIT2 
interactors13 and IntAct identifies at least 75 distinct GIT2 inter-
actors14. The introduction of high-dimensionality proteomics-
based protein complex analysis has greatly expanded the ability 
to discover both direct binary and co-complex binding partners 
(133–136). We believe that due to its widespread expression 
(46) and modular structure, GIT2 is likely to possess a broad 
spectrum of potential interacting partners and therefore our 
finding of a large number of potentially interacting proteins 
may not unexpected. GIT2 possesses multiple protein–protein 
interaction domains including a GAP (GTPase-activating 
protein) domain, two paxilin-binding subdomains (PBS1, 
PBS2), three ankyrin repeats, a Spa2-homology domain (SHD), 
a focal adhesion-targeting homology (FAH) domain, a coiled-
coil region, a leucine zipper motif, and a synaptic localization 
domain (111). Hub or keystone proteins, which we contend 
GIT2 may be, are considered to play a potentially pivotal 
role in organizing complex molecular signaling networks via 
their ability to exert a more trophic level of signaling control 
(137–139). Using an unbiased discovery process of identifying 
proteins controlling multidimensional neurometabolic signal-
ing networks in aging, we previously sought to discover target 
proteins that were associated with significantly more multiple 
signaling pathways compared to other proteins (13). Therefore, 
it not surprising that GIT2 may indeed function as a hub protein 
as aging affects nearly every physiological system in the body. 
The seemingly large array of protein interactions suggested for 
such hub proteins may reflect the ability of multiple proteoforms 
of the same protein to interact physically with several distinct 
signaling protein complexes simultaneously (140). Therefore, for 
any given protein, there are likely to be an ensemble of diverse 
interactomes that, unless differentially purified, will generate the 
appearance of a huge number of potential interacting proteins.
Highly connected hub proteins have been intensively studied 
in recent years as they potentially represent important therapeu-
tic targets (141). Hub proteins have been themselves categorized 
into two general types, i.e., “Party hubs” and “Date hubs” (139, 
142). The “Party” types are hubs whose expression is correlated 
with the expression levels of their interaction partners while 
“Date” types do not demonstrate this correlation. Linked to this 
distinction “Party” hubs are considered more likely to connect 
proteins within functional signaling modules, while “Date” hubs 
are more likely to connect different functional signaling modules. 
”Party” hubs are generally considered to be multi-interface pro-
teins whereas “Date” hubs are more frequently single-interaction 
interface proteins (143). However, such strong distinctions of the 
nature of hub proteins though are unlikely to be indicative of the 
reality of multifunctional proteins (144, 145). In the case of GIT2, 
and potentially many other “hub” proteins it is likely that it can, 
at various times depending on the specific cellular context, act as 
a “Party” hub, e.g., controlling skeletal dynamics, and act at times 
as a “Date” hub and cross-regulate multiple pathways involved in 
13 http://thebiogrid.org/
14 http://www.ebi.ac.uk/intact/
aging and metabolism, e.g., glycemic signaling and DNA repair. 
With regards to the pathophysiological functionality of GIT2, it is 
interesting to note that research over the last decade has generally 
concluded that human disease is rarely the consequence of an 
isolated abnormality in a particular gene or protein but is prob-
ably due to a series of complex perturbations in an underlying 
cellular network (141), in this case the neurometabolic “axis.” 
The structure of these networks/axes is likely governed, at some 
level by “hub” or keystone proteins, whose alterations can exert 
changes in their global properties thus linking their function 
to multiple disease processes (141, 146, 147). Further research 
into hub protein function is likely to uncover the biological sig-
nificance of these network controllers in disease etiology (147) as 
well as help in the delineation of trophic biomarkers and novel 
drug targets (141).
Our multifactorial analyses concerning the physiological 
status of the GIT2KO mice reveals a potentially important fac-
tor for the generation of aging trajectories, i.e., the metabolic 
shift away from primary glucose use to glucose/adipose use and 
then finally to adipose/protein use. Each of these transitions 
results in the reduction of RER away from a value of 1.0, i.e., 
glucose as primary energy source, toward 0.85–0.8, i.e., glucose/
adipose as primary energy source or toward <0.8, i.e., adipose/
protein as a primary energy source. Our observed decline in RER 
of relatively young GIT2KO mice is in line with reports of age-
dependent shifts in C57BL/6 mice (148). Maintaining metabolic 
efficiency, through preservation of the utilization of glucose as 
the primary energy source, in early and later life, will potentially 
reduce hyperglycemia-induced chronic inflammation (149, 
150), attenuate generation of ROS (151, 152), and also support 
the activity of energetic processes such as membrane electrical 
excitability (153), activity of cation pumps (154), unfolded 
protein management (155, 156) and nucleic acid damage (157, 
158). Therefore, in-part, the transition from “healthy” aging to 
“pathological” aging may coincide with a significant downshift 
in RER as nearly all of the processes entrained by energy insuf-
ficiency result in feed-forward pathological loops. An enhanced 
understanding of the molecular events that could predict this 
event would therefore provide potential remedial mechanisms 
to postpone this transition. As GIT2 possesses important roles 
in stress sensitivity (18, 19, 159), aging (13), and somatic energy 
management, this molecule potentially provides a novel target 
for therapies designed to interdict pathological aging and age-
related disease. With respect to potential therapeutic exploita-
tion of this keystone factor, our transcriptomic and proteomic 
analyses have demonstrated that GIT2 is strongly linked with 
multiple therapeutically tractable protein targets, e.g., glyoxylase 
1 [Glo1: Figure 8 (160–163)] and sestrin 1 [Sesn1: Figure 8; (82, 
92, 164, 165)]. Considerable further experimentation will be 
clearly required to uncover the optimal therapeutic mechanisms 
of exploiting GIT2 expression for the remediation of age-related 
pathologies, however, at the present time, it represents an 
interesting new master-regulator of the neurometabolic aging 
process.
With the advent of such a nuanced hierarchical approach, 
specifically of functional keystone factors, to the understanding 
January 2016 | Volume 6 | Article 19123
Martin et al. GIT2 Regulation of Neurometabolism
Frontiers in Endocrinology | www.frontiersin.org
of physiological and disease protein networks our concept of 
disease causation needs to take this into account. If potential 
keystone factors such as GIT2 are more important than other 
proteins with respect to their organization of other signaling 
modalities, it would be presumed that genomic deletion/modi-
fication may result in the generation of significant health issues. 
In our hands, aside from the metabolic alterations studied here, 
we have found that with post-mortem tissue extraction from 
aged GIT2KO males (12–18 months of age), we have identified 
consistent structural deformation of their upper gut (primarily 
ileal distention) as well as renal/hepatic adipose deposition. It 
is interesting to note however that potential “hub” or keystone 
proteins, as we propose GIT2 to be an example of, while being 
crucial for the organization of complex molecular events are not 
often the sole causes of disease (114, 166). Due to their trophic 
level of signaling pathway interactivity hub proteins are not 
often observed as genomic loci of disease (142) but if they are 
perturbed they will likely generate a wide spectrum of related 
pathologies. For example, genetic alteration of GIT2 has been 
identified in a GWAS risk allele screen for MetS (167). MetS rep-
resents a multifactorial disorder including an incredibly broad 
array of pathophysiologies including hypertriglyceridemia, 
insulin resistance, hypertension, vascular inflammation, athero-
sclerosis and renal, liver, and heart diseases (168). Therefore, it 
is perhaps not surprising that the GIT2KO mice do not present 
such a singular dramatic pathological phenotype as the effects 
of GIT2 deletion are likely to be highly multidimensional: GIT2 
genomic deletion has already been shown to affect central nerv-
ous system aging and DNA repair (18), immune function (169), 
bone mineral density, bone marrow adiposity (170), and anxiety/
stress phenotypic behavior (159). Also, associated with issues 
of congenital knockout models, it is clear that there is a strong 
reflexive survival response of the GIT2KO mice to metabolic 
disruption. For example, we have noted that while presenting a 
distinct metabolic phenotype, male GIT2KO mice on a regular 
chow diet (not high in fat or glucose) maintain a relatively 
similar bodyweight across their moderately reduced total life 
span. This interesting phenomenon is currently the subject of 
our ongoing research. In addition, the GIT2KO mice appear to 
be attempting to systemically ameliorate the deleterious effects 
of elevated glucose levels by increasing the expression of Glo1. 
Protracted exposure to excessive blood glucose can lead to the 
formation and accumulation of advanced glycation endproducts 
(AGEs) that are related to diabetes and other age-related diseases. 
Methylglyoxal (MGO), a highly reactive dicarbonyl compound, 
is considered to be one of the major precursor in the forma-
tion of AGEs and therefore is strongly implicated in accelerated 
pathophysiological aging mechanisms linked to metabolic 
instability (89). MGO is a cytotoxic, atherogenic (171), and neu-
rotoxic (172) glycolytic intermediate that is elevated in diabetic 
patients (173, 174) as well as those with cognitive decline (175). 
Under physiological circumstances, MGO is detoxified by the 
glyoxalase system into D-lactate, with Glo1 as the key enzyme in 
the anti-glycation defense. Therefore, it is likely that congenital 
models of metabolic disruption, associated with a premature 
aging such as GIT2KO mice, may indeed help illuminate many 
of the endogenous protective mechanisms at the same time 
as demonstrating the pathophysiological effects of the genetic 
disruption.
Our observations that GIT2 expression is modulated by 
stress (18, 19), aging (13) and metabolic pathologies (db/db) 
underscores the contextuality of what we consider to be “aging.” 
Therefore, rather than the process of aging being dictated merely 
by simple chronology, the effective physiological rate of aging 
(linked to damage accumulation) is considerably plastic and 
is contingent on the interaction and coordination of, multiple 
pathophysiological signaling pathways simultaneously across 
multiple tissues of the body. Acting as a protein with an ability 
to integrate numerous physiological processes intrinsic to the 
control of healthy aging, e.g., GPCR signaling systems (176), 
insulin/IGF-1 signaling systems (177), neurometabolic trans-
port processes (178, 179), DNA damage repair (39), cytoskeletal 
organization (180), and energy metabolism (181) GIT2 may 
represent an important target for both further diagnostic and 
therapeutic research for age-related disorders. An important 
component of this future research however should be dedicated 
to the appreciation of how these differential cellular require-
ments may interact with each other via their co-dependence 
on this interesting keystone protein (Figure 11). Hence a more 
nuanced and contextually sensitive understanding of how mul-
tiple complex signaling systems are integrated and regulated will 
profoundly enhance our appreciation, and hopefully successful 
treatment, of age-related disorders.
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